News - ONL Therapeutics

News

ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference

February 2, 2023
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution

February 1, 2023
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research

January 26, 2023
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study

July 12, 2022
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer

February 9, 2022
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones

January 13, 2022
ONL Therapeutics Names Connie Chang as Chief Operating Officer

January 19, 2021
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications

December 22, 2020
ONL Therapeutics featured on the OIS Retina Podcast

June 30, 2020

Privacy Statement | Accessibility Statement | Terms of Use | Copyright All Rights Reserved ©2024